Application of reagent for detecting methylation level of target region in preparation of endometrial cancer detection product and kit

Through a kit that detects the methylation level of specific regions of the PTPRT gene, non-invasive detection of cervical shedding cells is solved, and the problem of low sensitivity and specificity of endometrial cancer detection in the prior art has been solved, achieving higher Diagnostic accuracy and patient acceptance.

CN118685529BActive Publication Date: 2024-11-19湖南宏雅基因技术有限公司
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411170357.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-08-26
Publication Date
2024-11-19
Estimated Expiration
2044-08-26

AI Technical Summary

Technical Problem

The existing early detection methods for endometrial cancer have problems with low specificity and sensitivity, and most of the methods are invasive operations and have poor patient acceptance.

Method used

A kit for detecting the methylation level of a specific region of the PTPRT gene was used to detect non-invasively detect cervical shedding cells through methylation-specific PCR, bisulfite sequencing and other technologies, combined with digital PCR.

Benefits of technology

It improves the sensitivity and specificity of early diagnosis of endometrial cancer, provides a non-invasive and convenient detection method, and enhances patient acceptance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118685529B_ABST
    Figure CN118685529B_ABST
Patent Text Reader

Abstract

The present invention provides an application of a reagent for detecting the methylation level of a target region in the preparation of an endometrial cancer detection product and a kit, and relates to the technical field of endometrial cancer detection; the target region includes: a positive fragment of the PTPRT gene Chr20:43189602-43190501; a negative fragment of the PTPRT gene Chr20:43189602-43190501. The present invention uses digital PCR to detect endometrial cancer, which can provide higher detection sensitivity and specificity for the early clinical diagnosis of endometrial cancer; and compared with endometrial biopsy, the detection method of the present invention uses cervical exfoliated cells, which is a non-invasive test and can improve the patient's acceptance; compared with endometrial cytology detection, the detection method of the present invention has lower personnel requirements, is more convenient to operate, and is easier to promote technology.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of endometrial cancer detection, and in particular to an application of a reagent for detecting the methylation level of a target region in the preparation of an endometrial cancer detection product and a kit. Background Art

[0002] Endometrial cancer is an epithelial tumor on the endometrium caused by abnormal proliferation of endometrial cells. It has a high incidence among malignant tumors of the female reproductive system and poses a serious threat to women's health.

[0003] At present, the methods for early detection of endometrial cancer are mainly clinically imaging examinations, serum tumor markers CA125 and CA153, cytology, and the gold standard method of diagnostic curettage and hysteroscopic biopsy, but these diagnostic methods have certain limitations. Imaging examinations include B-ultrasound, CT, and MRI, and auxiliary examinations are used to diagnose endometrial cancer, but their specificity is low. The sensitivity and specificity of laboratory tests are low, imaging examinations cannot effectively detect early canceration, and the serum tumor marker CA125 has a low positive rate for patients with endometrial cancer and benign uterine lesions. Due to the multifocal nature of endometrial lesions, there are certain false negatives in biopsies, and endometrial biopsy is an invasive operation that can easily cause physical discomfort and poor patient compliance. Therefore, there is an urgent need to explore a non-invasive detection method that can assist in the diagnosis of endometrial cancer and has high sensitivity and specificity.

[0004] DNA methylation refers to the process in which an organism transfers a methyl group to a specific base using S-adenosylmethionine (SAM) as a methyl donor under the catalysis of DNA methyltransferase. DNA methylation can cause changes in chromatin structure, DNA conformation, DNA stability, and the way DNA interacts with proteins, thereby affecting gene expression. Common DNA methylation is the methylation of the carbon atom at position 5 of cytosine (C) in CpG. The methylation of C in CpG is converted into uracil (U) under the action of bisulfite, and then thymine (T) is generated through the action of desulfonation. Cytosine that has not been methylated does not change under the action of bisulfite, so that methylated cytosine and unmethylated cytosine can be distinguished.

[0005] The PTPRT (protein tyrosine phosphatase receptor type T) gene is a T-type protein tyrosine phosphatase receptor. The protein encoded by this gene is a member of the protein tyrosine phosphatase (PTP) family. PTP is a signaling molecule that regulates a variety of cellular processes, including cell growth, differentiation, mitotic cycle, and oncogenic transformation. Changes in the expression pattern of the PTPRT gene are associated with many human diseases, especially in the development of tumors, where epigenetics may play a key regulatory role. Summary of the invention

[0006] The present invention provides an application of a reagent for detecting the methylation level of a target region in the preparation of an endometrial cancer detection product, wherein the target region includes:

[0007] PTPRT gene Chr20:43189602-43190501 positive fragment;

[0008] PTPRT gene Chr20:43189602-43190501 negative fragment.

[0009] Furthermore, the reagent detects the methylation level of the target region by one or more of the following methods:

[0010] Methylation-specific PCR, bisulfite sequencing, methylation-specific microarray, whole-genome bisulfite sequencing, pyrosequencing, methylation-specific high-performance liquid chromatography, digital PCR, methylation-specific high-resolution melting curve method, methylation-sensitive restriction endonuclease method and methylation-specific fluorescent quantitative PCR method.

[0011] Furthermore, the reagent includes a nucleic acid combination for detecting the methylation level of the target region.

[0012] Further, the nucleic acid combination detects the methylation level of the target region by digital PCR, and the nucleic acid combination includes a detection primer pair for detecting the methylation level of the target region;

[0013] Wherein, the nucleic acid combination for detecting the methylation level of the positive fragment includes a front primer as shown in SEQ ID NO.1 and a rear primer as shown in SEQ ID NO.2;

[0014] The nucleic acid combination for detecting the methylation level of the negative fragment includes a front primer as shown in SEQ ID NO.4 and a rear primer as shown in SEQ ID NO.5.

[0015] Furthermore, the nucleic acid combination also includes a detection probe for detecting the methylation level of the target region.

[0016] Wherein, the nucleic acid combination for detecting the methylation level of the positive fragment includes the probe shown in SEQ ID NO.3;

[0017] The nucleic acid combination for detecting the methylation level of the negative fragment includes the probe shown in SEQ ID NO.6.

[0018] Furthermore, the sample types detected include cell samples, blood samples or tissue samples.

[0019] The present invention also provides an endometrial cancer diagnosis kit, comprising the reagent as described above.

[0020] Compared with the prior art, the present invention has the following beneficial effects:

[0021] 1. Compared with endometrial biopsy, the detection method of the present invention uses cervical exfoliated cells, which is a non-invasive test and can improve patient acceptance; 2. Compared with endometrial cytology detection, the detection method of the present invention has lower personnel requirements, more convenient operation, and easier technology promotion; 3. The present invention uses digital PCR to detect endometrial cancer, which can provide higher detection sensitivity and specificity for the early clinical diagnosis of endometrial cancer.

[0022] In addition to the above-described purposes, features and advantages, the present invention has other purposes, features and advantages. The present invention will be further described in detail with reference to the accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] The drawings constituting a part of this application are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute an improper limitation of the present invention. In the drawings:

[0024] FIG. 1 (a) is a scatter diagram of a positive sample of a PTPRT gene digital PCR analysis after the FAM detection channel in the quantitative PCR is used to detect the positive sample in the experimental example of the present invention;

[0025] FIG. 1 (b) is a scatter diagram of the positive samples of the PTPRT gene digital PCR analysis after the HEX detection channel in the quantitative PCR is used to detect the positive samples in the experimental example of the present invention;

[0026] FIG1( c ) is a scatter diagram of the negative samples of the PTPRT gene digital PCR analysis after the FAM detection channel in the quantitative PCR was used to detect the negative samples in the experimental example of the present invention;

[0027] FIG. 1 (d) is a scatter diagram of the negative samples of the PTPRT gene digital PCR analysis after the HEX detection channel in the quantitative PCR is used to detect the negative samples in the experimental example of the present invention;

[0028] Figure 2 This is the subject curve of PTPRT gene amplification in diagnosing endometrial cancer in the experimental example of the present invention. DETAILED DESCRIPTION

[0029] The following are specific embodiments of the present invention and the accompanying drawings to further describe the technical solution of the present invention, but the present invention is not limited to these embodiments.

[0030] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art of the present invention. The terms used in the present invention specification herein are only for the purpose of describing specific embodiments and are not intended to limit the present invention. Embodiment 1:

[0031] The gene methylation marker PTPRT gene for early screening and diagnosis of endometrial cancer is provided. The methylation region is selected from Reference GRCh38.p14 Primary Assembly Chr20:43189602-43190501, and its original sequence is as follows:

[0032] TGTGTGCGCGCGCGCGCTCTTAGATGAAATTCTCATCTCAGGGTGTGCCCGAGACCCTGGCCAGCAGCCGCCTGCCCCAGCTTTGGGCAGACGCCCCCACCCGCTTTCGCAATTCACCTGGCCCCTTATCTTGAGTTGCGAGGGCTGCTCCCTCCCTCCCTCTTCTCGCCACCGAACCCCCATTCACCTGTTCCCCACCCCGAGTTCAAACGGCTGCTGCAGCTTCCTCCTCCCCGCACCGCCCCCGTACCTGCGCCCCCACAGGGCAGACGATGCTTGGCTGCGCGGCGCGGCGCGGGGCGAAGAGGCGAGGACCCTGCCCGGCGTGTGGGTGCGGGGGTGATGTGTGGACGCGCGTGACTGTGCCAGCGGCCCGAGCTGGTCGGCCCCGGAGAGGGTGCGCGGGGGAGCCCGCGTGTGCCAGCCGCGGGCGTGTGCCAGGCGCGGGCGTGCGCGTGAGGGTGTGTGCACGGCCGAGGCGGAGCGCCCGGGCGGGCGGCGGCGGCGGCGGCGGCAACGGCGGCGGCGTTAGGACTCGGGGGACACCGCCCCCCGCCCCCCGCGTCCCGCCCCCGCCCAGCCTCCCGCCTCAGTTCGCGCCGCGCCTCGGCTTGGAACGCAGGAGCGCCGGCTCCGGGAGCCCGAGCGGAGCCAGCCGCGCGCACAGCCAGCGGCCGCGCCGGCGATGCGGGGCCACCCCGCGCCCGCCCCAGTCCCGGCCCCGGCCCCCGCGGGAAGGGGCTGAGCTGCCCGCCGCCGCCCGGATGGCGAGCCTCGCCGCGCTCGCCCTCAGCCTGCTCCTGAGGCTGCAGCTGCCGCCACTGCCCGGCGCCCGGGCTCAGAGCGCCGCAGGTGAGTGCGCCCGCCCGGCTCCCCTGGGCTCCCCGCTCCCTCCTG

[0033] The positive sequences after bisulfite treatment are as follows:

[0034] TGTGTGCGCGCGCGCGTTTTTAGATGAAATTTTTATTTTAGGGTGTGTTCGAGATTTTGGTTAGTAGTCGTTTGTTTTAGTTTTGGGTAGACGTTTTTATTCGTTTTCGTAATTTATTTGGTTTTTTATTTTGAGTTGCGAGGGTTGTTTTTTTTTTTTTTTTTTTCGTTATCGAATTTTTATTTATTTGTTTTTTATTTCGAGTTTAAACGGTTGTTGTAGTTTTTTTTTTTTCGTATCGTTTTCGTATTTGCGTTTTTATAGGGTAGACGATGTTTGGTTGCGCGGCGCGGCGCGGGGCGAAGAGGCGAGGATTTTGTTCGGCGTGTGGGTGCGGGGGTGATGTGTGGACGCGCGTGATTGTGTTAGCGGTTCGAGTTGGTCGGTTTCGGAGAGGGTGCGCGGGGGAGTTCGCGTGTGTTAGTCGCGGGCGTGTGTTAGGCGCGGGCGTGCGCGTGAGGGTGTGTGTACGGTCGAGGCGGAGCGTTCGGGCGGGCGGCGGCGGCGGCGGCGGCGGTAACGGCGGCGGCGTTAGGATTCGGGGGATATCGTTTTTCGTTTTTCGCGTTTCGTTTTCGTTTAGTTTTTCGTTTTAGTTCGCGTCGCGTTTCGGTTTGGAACGTAGGAGCGTCGGTTTCGGGAGTTCGAGCGGAGTTAGTCGCGCGTATAGTTAGCGGTCGCGTCGGCGATGCGGGGTTATTTCGCGTTCGTTTTAGTTTCGGTTTCGGTTTTCGCGGGAAGGGGTTGAGTTGTTCGTCGTCGTTCGGATGGCGAGTTTCGTCGCGTTCGTTTTTAGTTTGTTTTTGAGGTTGTAGTTGTCGTTATTGTTCGGCGTTCGGGTTTAGAGCGTCGTAGGTGAGTGCGTTCGTTCGGTTTTTTTGGGTTTTTCGTTTTTTTTTG

[0035] The negative sequences after bisulfite treatment are as follows:

[0036] TGTGTGTGTGTGTGTGTTTTTAGATGAAATTTTTATTTTAGGGTGTGTTTGAGATTTTGGTTAGTAGTTGTTTGTTTTAGTTTTGGGTAGATGTTTTTATTTGTTTTTGTAATTTATTTGGTTTTTTATTTTGAGTTGTGAGGGTTGTTTTTTTTTTTTTTTTTTTTGTTATTGAATTTTTATTTATTTGTTTTTTATTTTGAGTTTAAATGGTTGTTGTAGTTTTTTTTTTTTTGTATTGTTTTTGTATTTGTGTTTTTATAGGGTAGATGATGTTTGGTTGTGTGGTGTGGTGTGGGGTGAAGAGGTGAGGATTTTGTTTGGTGTGTGGGTGTGGGGGTGATGTGTGGATGTGTGTGATTGTGTTAGTGGTTTGAGTTGGTTGGTTTTGGAGAGGGTGTGTGGGGGAGTTTGTGTGTGTTAGTTGTGGGTGTGTGTTAGGTGTGGGTGTGTGTGTGAGGGTGTGTGTATGGTTGAGGTGGAGTGTTTGGGTGGGTGGTGGTGGTGGTGGTGGTAATGGTGGTGGTGTTAGGATTTGGGGGATATTGTTTTTTGTTTTTTGTGTTTTGTTTTTGTTTAGTTTTTTGTTTTAGTTTGTGTTGTGTTTTGGTTTGGAATGTAGGAGTGTTGGTTTTGGGAGTTTGAGTGGAGTTAGTTGTGTGTATAGTTAGTGGTTGTGTTGGTGATGTGGGGTTATTTTGTGTTTGTTTTAGTTTTGGTTTTGGTTTTTGTGGGAAGGGGTTGAGTTGTTTGTTGTTGTTTGGATGGTGAGTTTTGTTGTGTTTGTTTTTAGTTTGTTTTTGAGGTTGTAGTTGTTGTTATTGTTTGGTGTTTGGGTTTAGAGTGTTGTAGGTGAGTGTGTTTGTTTGGTTTTTTTGGGTTTTTTGTTTTTTTTTG

[0037] According to the converted positive and negative sequences of the selected fragment, primer and probe design was carried out, and the primer design is shown in Table 1.

[0038] Table 1: Nucleic acid sequences of the detected genes and primers and probes

[0039]

[0040] The positive fragment probe sequence shown in the table is labeled with a fluorescent group of FAM, the negative fragment probe sequence is labeled with a fluorescent group of HEX, and the quenching group is one of BHQ1, BHQ2, BHQ3, TAMRA, DABCYL, and MGB. Embodiment 2:

[0041] 1. Sample DNA Extraction

[0042] The nucleic acid extraction or purification reagents produced by Hunan Hongya Gene Technology Co., Ltd. were used to extract DNA from cervical exfoliated cell samples. The quality of the extracted DNA was monitored and the total amount of DNA was between 200-1000ng.

[0043] 2. Bisulfite treatment

[0044] Take 500 ng DNA (DNA volume does not exceed 50 μL) and add it to a 0.2 mL PCR tube, add 100 μL conversion reagent mixture, shake and mix, then centrifuge, and then perform chemical reaction according to the parameters shown in Table 2.

[0045] Table 2: Bisulfite treatment procedures

[0046]

[0047] After the end, take out the PCR tube and perform the desulfonation reaction and nucleic acid purification according to the following steps:

[0048] Step 1: Take a sterilized 1.5 ml centrifuge tube, add 600 μl of binding solution and 20 μl of magnetic beads and mix well.

[0049] Note: Please mix the magnetic bead solution evenly before use.

[0050] Step 2: After adding the sample that has completed the chemical reaction, shake it evenly several times.

[0051] Step 3: Place the centrifuge tube on the magnetic stand and make sure that the magnetic beads in the centrifuge tube are adsorbed to the tube wall.

[0052] Step 4: Take out the liquid in the centrifuge tube and avoid adsorbing the magnetic beads on the tube wall.

[0053] Note: Please try to drain the liquid as much as possible to avoid interfering with subsequent experimental steps.

[0054] Step 5. Add 200 μl of washing solution, remove the centrifuge tube from the magnetic rack and shake until uniform.

[0055] Step 6. Place the centrifuge tube on the magnetic rack and confirm that the magnetic beads in the centrifuge tube are adsorbed to the tube wall.

[0056] Step 7. Draw out as much liquid as possible from the centrifuge tube and avoid adsorbing the magnetic beads on the tube wall.

[0057] Step 8. Add 200 μl of desulfonation solution, remove the centrifuge tube from the magnetic rack, shake until evenly mixed, and leave at room temperature for 20 minutes.

[0058] Step 9. Place the centrifuge tube on the magnetic rack and confirm that the magnetic beads in the centrifuge tube are adsorbed to the tube wall.

[0059] Step 10. Draw out as much liquid as possible from the centrifuge tube and avoid adsorbing the magnetic beads on the tube wall.

[0060] Step 11. Repeat steps 5 to 7 twice.

[0061] Step 12: After removing the centrifuge tube from the magnetic rack, place the centrifuge tube with the liquid drained in a 56°C dry bath for 10 minutes and then take it out.

[0062] Step 13. Add 50 μl of extraction solution, shake evenly several times, and leave at room temperature for 5 minutes.

[0063] Note: The eluent should be preheated in a 56°C dry bath before use.

[0064] Step 14: Place the centrifuge tube on the magnetic rack and confirm that the magnetic beads in the centrifuge tube are adsorbed to the tube wall.

[0065] Step 15. Aspirate the liquid in the centrifuge tube as much as possible (avoid removing the magnetic beads during the process) and place it in another 1.5 ml centrifuge tube to complete DNA recovery.

[0066] 3. Droplet Preparation

[0067] The PCR system was prepared according to the parameters shown in Table 3.

[0068] Table 3: Fluorescence quantitative PCR system

[0069]

[0070] After preparation, dispense 18 μL of the mixed Mix into a PCR tube, add 2 μL of treated DNA, and mix well. Centrifuge the mixed reaction solution instantaneously and add all of it to the droplet preparation instrument of Zhenzhun Biotechnology (Shanghai) Co., Ltd. After all droplets are added to the chip, use 50 μL of sealing oil to seal the chip to complete the droplet preparation.

[0071] IV. PCR Amplification and Chip Reading

[0072] The PCR program was set according to the parameters shown in Table 4.

[0073] Table 4: Digital PCR program

[0074]

[0075] The prepared chip was placed on the thermal amplification instrument of Zhenzhun Biotech (Shanghai) Co., Ltd. for amplification. After the amplification, the chip was placed on the reading analyzer AccuONE of Zhenzhun Biotech (Shanghai) Co., Ltd., and the exposure of the FAM channel and the HEX channel were both selected to be 5% for analysis.

[0076] 5. Interpretation of gene methylation results

[0077] Effective number of holes>10000;

[0078] Methylation rate of methylation sites (%) = number of FAM channel detections / (number of FAM channel detections + number of HEX channel detections) × 100%.

[0079] Experimental example:

[0080] 74 cases of cervical exfoliated cells with known clear pathological results were selected, including 24 patients with endometrial cancer, 20 patients with uterine fibroids or endometrial polyps, and 30 normal patients. According to Example 2, DNA in the cervical exfoliated cell samples was extracted, bisulfite converted and digital PCR detected and analyzed. According to the methylation rate calculation formula: methylation rate = FAM channel detection number / (FAM channel detection number + HEX channel detection number), the methylation rate of the site of each sample was obtained, and the results are shown in Table 5.

[0081] Table 5: PTPRT gene digital PCR detection results

[0082]

[0083] Receiver operating curve analysis was performed on the PTPRT gene. Endometrial cancer was used as the cut-off point and the maximum Youden index was used as the principle to determine the positive judgment value. The results are shown in Table 6.

[0084] Table 6: Subject curve analysis of PTPRT gene for endometrial cancer

[0085]

[0086] The PTPRT gene methylation test results and disease status of 74 samples were analyzed, and the results are shown in Table 7.

[0087] Table 7: PTPRT gene methylation detection results and disease status analysis

[0088]

[0089] The performance of PTPRT gene methylation detection of 74 samples was analyzed, and the results are shown in Table 8.

[0090] Table 8: PTPRT gene methylation detection performance analysis

[0091]

[0092] From the results, the area under the curve is 0.975, indicating that the detection of PTPRT gene methylation by digital PCR as a method for diagnosing endometrial cancer has very good diagnostic accuracy. With 19.58% as the positive judgment value, the sensitivity reached 95.83%, the specificity reached 92.00%, and the positive judgment value and negative judgment value both reached more than 85%. It can be seen that the kit of the present invention can provide higher diagnostic sensitivity and specificity in the clinical diagnosis of endometrial cancer.

[0093] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. Use of a reagent for detecting the methylation level of a target region in the preparation of an endometrial cancer detection product, characterized in that: The target areas include: PTPRT gene Chr20:43189602-43190501 positive fragment; PTPRT gene Chr20:43189602-43190501 negative fragment; The reagent for detecting the methylation level of the target region is a nucleic acid combination, and the nucleic acid combination detects the methylation level of the target region by a digital PCR method, and the nucleic acid combination includes a detection primer pair for detecting the methylation level of the target region and a detection probe for detecting the methylation level of the target region; Wherein, the nucleic acid combination for detecting the methylation level of the positive fragment includes a front primer as shown in SEQ ID NO.1 and a rear primer as shown in SEQ ID NO.2; The nucleic acid combination for detecting the methylation level of the negative fragment includes a front primer as shown in SEQ ID NO.4 and a rear primer as shown in SEQ ID NO.5; The nucleic acid combination for detecting the methylation level of the positive fragment includes the probe shown in SEQ ID NO.3; The nucleic acid combination for detecting the methylation level of the negative fragment includes the probe shown in SEQ ID NO.

6.

2. The use according to claim 1, characterized in that: The sample types tested include cell samples, blood samples or tissue samples.

3. A diagnostic kit for endometrial cancer, characterized in that: The method comprises the reagent as described in any one of claims 1 to 2.